Open AccessSuperoxide Dismutase, BDNF, and Cognitive Improvement in Drug-Naive First-Episode Patients With Schizophrenia: A 12-Week Longitudinal Study
Author(s) -
Zixiang Wu,
Qinqin Liu,
Yinghua Zhang,
Xiaoni Guan,
Meihong Xiu,
Xiangyang Zhang
Publication year - 2021
Publication title -
international journal of neuropsychopharmacology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.897
H-Index - 107
eISSN - 1469-5111
pISSN - 1461-1457
DOI - 10.1093/ijnp/pyab065
Subject(s) - risperidone , superoxide dismutase , schizophrenia (object oriented programming) , medicine , psychology , repeatable battery for the assessment of neuropsychological status , brain derived neurotrophic factor , cognition , neuropsychology , endocrinology , neurotrophic factors , psychiatry , pharmacology , oxidative stress , receptor
Cognitive improvement after antipsychotic agents in patients with schizophrenia (SCZ) appears to involve redox regulation through neurotrophins such as brain derived neurotropic factor (BDNF). This study examined whether cognitive improvement was associated with the increase in superoxide dismutase (SOD) and whether higher levels of BDNF could have a permissive role in allowing SOD to improve cognition.